Shopping Cart 0
Cart Subtotal
USD 0

North America Human Insulin Market 2020-2026 by Product Type (Drugs, Delivery Devices), Application (Type 1 Diabetes, Type 2 Diabetes, Others), Distribution Channel, and Country: Trend Forecast and Growth Opportunity

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 2480

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 3300

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 4100

Details

North America human insulin market is expected to reach USD 23.52 billion by 2025, growing by 7.36% annually over the next years.

Highlighted with 27 tables and 52 figures, this 105-page report North America Human Insulin Market 2020-2026 by Product Type (Drugs, Delivery Devices), Application (Type 1 Diabetes, Type 2 Diabetes, Others), Distribution Channel, and Country: Trend Forecast and Growth Opportunity is based on a comprehensive research of the entire North America human insulin market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. In this report 2019 is the base year for market analysis, with estimates and forecast covering 2020-2026. (Please Note: The report will be updated before delivery to make sure that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

In-depth qualitative analyses include identification and investigation of the following aspects:

o Market Structure

o Growth Drivers

o Restraints and Challenges

o Emerging Product Trends & Market Opportunities

o Porter's Fiver Forces

The trend and outlook of North America market is forecast in optimistic, balanced, and conservative view. The balanced (most likely) projection is used to quantify North America human insulin market in every aspect of the classification from perspectives of Product Type, Application, Distribution Channel, and Country.

Based on product type, the North America market is segmented into the following sub-markets with annual revenue for 2019-2026 included in each section.

o Human Insulin Drugs

o Human Insulin Delivery Devices

Based on product, the North America Human Insulin Drugs market is segmented into the following sub-markets with annual revenue for 2019-2026 included in each section.

o Modern Human Insulin (further segmented into Long-acting, Rapid- acting, Premixed by type; further segmented into Lantus, Apidra, Levemir, NovoRapid/ NovoLog, Novomix, Humalog, Others by brand)

o Traditional Human Insulin (further segmented into Short-acting, Intermediate & Rapid-acting, Premixed by type; further segmented into Humulin, Insuman, Novolin/Actrapid/Insulatard by brand)

Based on product, the North America Human Insulin Delivery Devices market is segmented into the following sub-markets with annual revenue for 2019-2026 included in each section.

o Syringes

o Pens (further segmented into Disposable, Reusable, Pen needles)

o Pumps

o Others

Based on application, the North America market is segmented into the following sub-markets with annual revenue for 2019-2026 included in each section.

o Type 1 Diabetes

o Type 2 Diabetes

o Gestational Diabetes and Prediabetes

Based on distribution channel, the North America market is segmented into the following sub-markets with annual revenue for 2019-2026 included in each section.

o Hospital Pharmacies

o Retail Pharmacies

o Online Pharmacies

Geographically, the following national/local markets are fully investigated:

o U.S.

o Canada

For each of the aforementioned countries, market analysis and revenue data are available for 2019-2026. The breakdown of major national markets by Product Type, Application, and Distribution Channel over the study years (2019-2026) is included.

The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.

Specifically, potential risks associated with investing in North America human insulin market are assayed quantitatively and qualitatively through GMD's Risk Assessment System. According to the risk analysis and evaluation, Critical Success Factors (CSFs) are generated as a guidance to help investors & stockholders identify emerging opportunities, manage and minimize the risks, develop appropriate business models, and make wise strategies and decisions.

Key Players:

Astra Zeneca PLC

Biocon

Eli Lilly

Exir

Julphar

Novo Nordisk AS

Pfizer

Sanofi Aventis

Sedico

Wockhardt

(Please Note: The report will be updated before delivery to make sure that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

READ MORE

Table Of Content

Scope

1 Introduction 5

1.1 Industry Definition and Research Scope 5

1.1.1 Industry Definition 5

1.1.2 Research Scope 6

1.2 Research Methodology 8

1.2.1 Overview of Market Research Methodology 8

1.2.2 Market Assumption 9

1.2.3 Secondary Data 9

1.2.4 Primary Data 9

1.2.5 Data Filtration and Model Design 10

1.2.6 Market Size/Share Estimation 11

1.2.7 Research Limitations 12

1.3 Executive Summary 13

2 Market Overview and Dynamics 15

2.1 Market Size and Forecast 15

2.2 Major Growth Drivers 16

2.3 Market Restraints and Challenges 19

2.4 Emerging Opportunities and Market Trends 22

2.5 Porter's Fiver Forces Analysis 25

3 Segmentation of North America Market by Product Type 29

3.1 Market Overview by Product Type 29

3.2 Human Insulin Drugs 31

3.3 Human Insulin Delivery Devices 32

4 Segmentation of North America Human Insulin Drugs Market by Drug Product 33

4.1 Market Overview by Drug Product 33

4.2 Modern Human Insulin 35

4.2.1 Modern Human Insulin by Type 37

4.2.2 Modern Human Insulin by Brand 41

4.3 Traditional Human Insulin 48

4.3.1 Traditional Human Insulin by Type 50

4.3.2 Traditional Human Insulin by Brand 53

5 Segmentation of North America Human Insulin Delivery Devices Market by Device Product 56

5.1 Market Overview by Product 56

5.2 Syringes 58

5.3 Pens 59

5.4 Pumps 60

5.5 Other Devices 62

6 Segmentation of North America Market by Application 63

6.1 Market Overview by Application 63

6.2 Type 1 Diabetes 65

6.3 Type 2 Diabetes 66

6.4 Gestational Diabetes and Prediabetes 67

7 Segmentation of North America Market by Distribution Channel 68

7.1 Market Overview by Distribution Channel 68

7.2 Hospital Pharmacies 70

7.3 Retail Pharmacies 71

7.4 Online Pharmacies 72

8 North America Market 2019-2026 by Country 73

8.1 Overview of North America Market 73

8.2 U.S. Market 76

8.3 Canadian Market 80

9 Competitive Landscape 82

9.1 Overview of Key Vendors 82

9.2 New Product Launch, Partnership, Investment, and M&A 86

9.3 Company Profiles 88

Astra Zeneca PLC 88

Biocon 90

Eli Lilly 91

Exir 92

Julphar 93

Novo Nordisk AS 94

Pfizer 95

Sanofi Aventis 96

Sedico 97

Wockhardt 98

10 Investing in North America Market: Risk Assessment and Management 99

10.1 Risk Evaluation of North America Market 99

10.2 Critical Success Factors (CSFs) 102

Related Reports and Products 105


List Of Figure

Figure 1. Research Method Flow Chart 8

Figure 2. Bottom-up Approach and Top-down Approach for Market Estimation 11

Figure 3. North America Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2019-2026 13

Figure 4. North America Human Insulin Market, 2019-2026, USD mn 15

Figure 5. Primary Drivers and Impact Factors of North America Human Insulin Market 16

Figure 6. Primary Restraints and Impact Factors of North America Human Insulin Market 19

Figure 7. Porter's Fiver Forces Analysis of North America Human Insulin Market 25

Figure 8. Breakdown of North America Human Insulin Market by Product Type, 2019-2026, % of Revenue 29

Figure 9. Contribution to North America 2020-2026 Cumulative Revenue by Product Type, Value (USD mn) and Share (%) 30

Figure 10. North America Human Insulin Market: Human Insulin Drugs, 2019-2026, USD mn 31

Figure 11. North America Human Insulin Market: Human Insulin Delivery Devices, 2019-2026, USD mn 32

Figure 12. Breakdown of North America Human Insulin Drugs Market by Product, 2019-2026, % of Revenue 33

Figure 13. Contribution to North America Human Insulin Drugs Cumulative Revenue by Product, 2020-2026, Value (USD mn) and Share (%) 34

Figure 14. North America Human Insulin Market: Modern Human Insulin, 2019-2026, USD mn 35

Figure 15. North America Modern Human Insulin Market: Long-acting, 2019-2026, USD mn 37

Figure 16. North America Modern Human Insulin Market: Rapid- acting, 2019-2026, USD mn 38

Figure 17. North America Modern Human Insulin Market: Premixed, 2019-2026, USD mn 40

Figure 18. North America Modern Human Insulin Market: Lantus, 2019-2026, USD mn 41

Figure 19. North America Modern Human Insulin Market: Apidra, 2019-2026, USD mn 42

Figure 20. North America Modern Human Insulin Market: Levemir, 2019-2026, USD mn 43

Figure 21. North America Modern Human Insulin Market: NovoRapid/ NovoLog, 2019-2026, USD mn 44

Figure 22. North America Modern Human Insulin Market: Novomix, 2019-2026, USD mn 45

Figure 23. North America Modern Human Insulin Market: Humalog, 2019-2026, USD mn 46

Figure 24. North America Modern Human Insulin Market: Other Brands, 2019-2026, USD mn 47

Figure 25. North America Human Insulin Market: Traditional Human Insulin, 2019-2026, USD mn 48

Figure 26. North America Traditional Human Insulin Market: Short-acting, 2019-2026, USD mn 50

Figure 27. North America Traditional Human Insulin Market: Intermediate & Rapid-acting, 2019-2026, USD mn 51

Figure 28. North America Traditional Human Insulin Market: Premixed, 2019-2026, USD mn 52

Figure 29. North America Traditional Human Insulin Market: Humulin, 2019-2026, USD mn 53

Figure 30. North America Traditional Human Insulin Market: Insuman, 2019-2026, USD mn 54

Figure 31. North America Traditional Human Insulin Market: Novolin/Actrapid/Insulatard, 2019-2026, USD mn 55

Figure 32. Breakdown of North America Human Insulin Delivery Devices Market by Product, 2019-2026, % of Revenue 56

Figure 33. Contribution to North America Human Insulin Delivery Devices Cumulative Revenue by Product, 2020-2026, Value (USD mn) and Share (%) 57

Figure 34. North America Human Insulin Delivery Devices Market: Syringes, 2019-2026, USD mn 58

Figure 35. North America Human Insulin Delivery Devices Market: Pens, 2019-2026, USD mn 59

Figure 36. North America Human Insulin Delivery Devices Market: Pumps, 2019-2026, USD mn 60

Figure 37. North America Human Insulin Delivery Devices Market: Other Devices, 2019-2026, USD mn 62

Figure 38. Breakdown of North America Human Insulin Market by Application, 2019-2026, % of Revenue 63

Figure 39. Contribution to North America 2020-2026 Cumulative Revenue by Application, Value (USD mn) and Share (%) 64

Figure 40. North America Human Insulin Market: Type 1 Diabetes, 2019-2026, USD mn 65

Figure 41. North America Human Insulin Market: Type 2 Diabetes, 2019-2026, USD mn 66

Figure 42. North America Human Insulin Market: Gestational Diabetes and Prediabetes, 2019-2026, USD mn 67

Figure 43. Breakdown of North America Human Insulin Market by Distribution Channel, 2019-2026, % of Revenue 68

Figure 44. Contribution to North America 2020-2026 Cumulative Revenue by Distribution Channel, Value (USD mn) and Share (%) 69

Figure 45. North America Human Insulin Market: Hospital Pharmacies, 2019-2026, USD mn 70

Figure 46. North America Human Insulin Market: Retail Pharmacies, 2019-2026, USD mn 71

Figure 47. North America Human Insulin Market: Online Pharmacies, 2019-2026, USD mn 72

Figure 48. Breakdown of North America Human Insulin Market by Country, 2019 and 2026, % of Revenue 74

Figure 49. Contribution to North America 2020-2026 Cumulative Revenue by Country, Value (USD mn) and Share (%) 75

Figure 50. U.S. Human Insulin Market, 2019-2026, USD mn 77

Figure 51. Canada Human Insulin Market, 2019-2026, USD mn 80

Figure 52. Growth Stage of North America Human Insulin Industry over the Forecast Period 82


List Of Table

Table 1. Snapshot of North America Human Insulin Market, 2019-2026 14

Table 2. Main Product Trends and Market Opportunities in North America Human Insulin Market 22

Table 3. North America Human Insulin Market by Product Type, 2019-2026, USD mn 29

Table 4. North America Human Insulin Drugs Market by Product, 2019-2026, USD mn 33

Table 5. North America Human Insulin Drugs Market: Modern Human Insulin by Type, 2019-2026, USD mn 36

Table 6. North America Human Insulin Drugs Market: Modern Human Insulin by Brand, 2019-2026, USD mn 36

Table 7. North America Human Insulin Drugs Market: Traditional Human Insulin by Type, 2019-2026, USD mn 49

Table 8. North America Human Insulin Drugs Market: Traditional Human Insulin by Brand, 2019-2026, USD mn 49

Table 9. North America Human Insulin Delivery Devices Market by Product, 2019-2026, USD mn 56

Table 10. North America Human Insulin Delivery Devices Market: Pens by Product, 2019-2026, USD mn 59

Table 11. North America Human Insulin Market by Application, 2019-2026, USD mn 63

Table 12. North America Human Insulin Market by Distribution Channel, 2019-2026, USD mn 68

Table 13. North America Human Insulin Market by Country, 2019-2026, USD mn 74

Table 14. U.S. Human Insulin Market by Product Type, 2019-2026, USD mn 78

Table 15. U.S. Human Insulin Market by Application, 2019-2026, USD mn 78

Table 16. U.S. Human Insulin Market by Distribution Channel, 2019-2026, USD mn 78

Table 17. Canada Human Insulin Market by Product Type, 2019-2026, USD mn 81

Table 18. Canada Human Insulin Market by Application, 2019-2026, USD mn 81

Table 19. Canada Human Insulin Market by Distribution Channel, 2019-2026, USD mn 81

Table 20. North America Human Insulin Market by Key Vendor, 2019, USD mn 84

Table 21. Astra Zeneca PLC: Company Snapshot 88

Table 22. Astra Zeneca PLC: Business Segmentation 88

Table 23. Astra Zeneca PLC: Product Portfolio 89

Table 24. Astra Zeneca PLC: Revenue, 2016-2018, USD mn 89

Table 25. Astra Zeneca PLC: Recent Developments 89

Table 26. Risk Evaluation for Investing in North America Market, 2019-2026 100

Table 27. Critical Success Factors and Key Takeaways 103

Licence Rights

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies


Companies

Astra Zeneca PLC

Biocon

Eli Lilly

Exir

Julphar

Novo Nordisk AS

Pfizer

Sanofi Aventis

Sedico

Wockhardt

Company Profile

Company Profile Title

North America human insulin market is expected to reach USD 23.52 billion by 2025, growing by 7.36% annually over the next years.

Highlighted with 27 tables and 52 figures, this 105-page report North America Human Insulin Market 2020-2026 by Product Type (Drugs, Delivery Devices), Application (Type 1 Diabetes, Type 2 Diabetes, Others), Distribution Channel, and Country: Trend Forecast and Growth Opportunity is based on a comprehensive research of the entire North America human insulin market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. In this report 2019 is the base year for market analysis, with estimates and forecast covering 2020-2026. (Please Note: The report will be updated before delivery to make sure that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

In-depth qualitative analyses include identification and investigation of the following aspects:

o Market Structure

o Growth Drivers

o Restraints and Challenges

o Emerging Product Trends & Market Opportunities

o Porter's Fiver Forces

The trend and outlook of North America market is forecast in optimistic, balanced, and conservative view. The balanced (most likely) projection is used to quantify North America human insulin market in every aspect of the classification from perspectives of Product Type, Application, Distribution Channel, and Country.

Based on product type, the North America market is segmented into the following sub-markets with annual revenue for 2019-2026 included in each section.

o Human Insulin Drugs

o Human Insulin Delivery Devices

Based on product, the North America Human Insulin Drugs market is segmented into the following sub-markets with annual revenue for 2019-2026 included in each section.

o Modern Human Insulin (further segmented into Long-acting, Rapid- acting, Premixed by type; further segmented into Lantus, Apidra, Levemir, NovoRapid/ NovoLog, Novomix, Humalog, Others by brand)

o Traditional Human Insulin (further segmented into Short-acting, Intermediate & Rapid-acting, Premixed by type; further segmented into Humulin, Insuman, Novolin/Actrapid/Insulatard by brand)

Based on product, the North America Human Insulin Delivery Devices market is segmented into the following sub-markets with annual revenue for 2019-2026 included in each section.

o Syringes

o Pens (further segmented into Disposable, Reusable, Pen needles)

o Pumps

o Others

Based on application, the North America market is segmented into the following sub-markets with annual revenue for 2019-2026 included in each section.

o Type 1 Diabetes

o Type 2 Diabetes

o Gestational Diabetes and Prediabetes

Based on distribution channel, the North America market is segmented into the following sub-markets with annual revenue for 2019-2026 included in each section.

o Hospital Pharmacies

o Retail Pharmacies

o Online Pharmacies

Geographically, the following national/local markets are fully investigated:

o U.S.

o Canada

For each of the aforementioned countries, market analysis and revenue data are available for 2019-2026. The breakdown of major national markets by Product Type, Application, and Distribution Channel over the study years (2019-2026) is included.

The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.

Specifically, potential risks associated with investing in North America human insulin market are assayed quantitatively and qualitatively through GMD's Risk Assessment System. According to the risk analysis and evaluation, Critical Success Factors (CSFs) are generated as a guidance to help investors & stockholders identify emerging opportunities, manage and minimize the risks, develop appropriate business models, and make wise strategies and decisions.

Key Players:

Astra Zeneca PLC

Biocon

Eli Lilly

Exir

Julphar

Novo Nordisk AS

Pfizer

Sanofi Aventis

Sedico

Wockhardt

(Please Note: The report will be updated before delivery to make sure that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

READ MORE

Scope

1 Introduction 5

1.1 Industry Definition and Research Scope 5

1.1.1 Industry Definition 5

1.1.2 Research Scope 6

1.2 Research Methodology 8

1.2.1 Overview of Market Research Methodology 8

1.2.2 Market Assumption 9

1.2.3 Secondary Data 9

1.2.4 Primary Data 9

1.2.5 Data Filtration and Model Design 10

1.2.6 Market Size/Share Estimation 11

1.2.7 Research Limitations 12

1.3 Executive Summary 13

2 Market Overview and Dynamics 15

2.1 Market Size and Forecast 15

2.2 Major Growth Drivers 16

2.3 Market Restraints and Challenges 19

2.4 Emerging Opportunities and Market Trends 22

2.5 Porter's Fiver Forces Analysis 25

3 Segmentation of North America Market by Product Type 29

3.1 Market Overview by Product Type 29

3.2 Human Insulin Drugs 31

3.3 Human Insulin Delivery Devices 32

4 Segmentation of North America Human Insulin Drugs Market by Drug Product 33

4.1 Market Overview by Drug Product 33

4.2 Modern Human Insulin 35

4.2.1 Modern Human Insulin by Type 37

4.2.2 Modern Human Insulin by Brand 41

4.3 Traditional Human Insulin 48

4.3.1 Traditional Human Insulin by Type 50

4.3.2 Traditional Human Insulin by Brand 53

5 Segmentation of North America Human Insulin Delivery Devices Market by Device Product 56

5.1 Market Overview by Product 56

5.2 Syringes 58

5.3 Pens 59

5.4 Pumps 60

5.5 Other Devices 62

6 Segmentation of North America Market by Application 63

6.1 Market Overview by Application 63

6.2 Type 1 Diabetes 65

6.3 Type 2 Diabetes 66

6.4 Gestational Diabetes and Prediabetes 67

7 Segmentation of North America Market by Distribution Channel 68

7.1 Market Overview by Distribution Channel 68

7.2 Hospital Pharmacies 70

7.3 Retail Pharmacies 71

7.4 Online Pharmacies 72

8 North America Market 2019-2026 by Country 73

8.1 Overview of North America Market 73

8.2 U.S. Market 76

8.3 Canadian Market 80

9 Competitive Landscape 82

9.1 Overview of Key Vendors 82

9.2 New Product Launch, Partnership, Investment, and M&A 86

9.3 Company Profiles 88

Astra Zeneca PLC 88

Biocon 90

Eli Lilly 91

Exir 92

Julphar 93

Novo Nordisk AS 94

Pfizer 95

Sanofi Aventis 96

Sedico 97

Wockhardt 98

10 Investing in North America Market: Risk Assessment and Management 99

10.1 Risk Evaluation of North America Market 99

10.2 Critical Success Factors (CSFs) 102

Related Reports and Products 105


List Of Figure

Figure 1. Research Method Flow Chart 8

Figure 2. Bottom-up Approach and Top-down Approach for Market Estimation 11

Figure 3. North America Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2019-2026 13

Figure 4. North America Human Insulin Market, 2019-2026, USD mn 15

Figure 5. Primary Drivers and Impact Factors of North America Human Insulin Market 16

Figure 6. Primary Restraints and Impact Factors of North America Human Insulin Market 19

Figure 7. Porter's Fiver Forces Analysis of North America Human Insulin Market 25

Figure 8. Breakdown of North America Human Insulin Market by Product Type, 2019-2026, % of Revenue 29

Figure 9. Contribution to North America 2020-2026 Cumulative Revenue by Product Type, Value (USD mn) and Share (%) 30

Figure 10. North America Human Insulin Market: Human Insulin Drugs, 2019-2026, USD mn 31

Figure 11. North America Human Insulin Market: Human Insulin Delivery Devices, 2019-2026, USD mn 32

Figure 12. Breakdown of North America Human Insulin Drugs Market by Product, 2019-2026, % of Revenue 33

Figure 13. Contribution to North America Human Insulin Drugs Cumulative Revenue by Product, 2020-2026, Value (USD mn) and Share (%) 34

Figure 14. North America Human Insulin Market: Modern Human Insulin, 2019-2026, USD mn 35

Figure 15. North America Modern Human Insulin Market: Long-acting, 2019-2026, USD mn 37

Figure 16. North America Modern Human Insulin Market: Rapid- acting, 2019-2026, USD mn 38

Figure 17. North America Modern Human Insulin Market: Premixed, 2019-2026, USD mn 40

Figure 18. North America Modern Human Insulin Market: Lantus, 2019-2026, USD mn 41

Figure 19. North America Modern Human Insulin Market: Apidra, 2019-2026, USD mn 42

Figure 20. North America Modern Human Insulin Market: Levemir, 2019-2026, USD mn 43

Figure 21. North America Modern Human Insulin Market: NovoRapid/ NovoLog, 2019-2026, USD mn 44

Figure 22. North America Modern Human Insulin Market: Novomix, 2019-2026, USD mn 45

Figure 23. North America Modern Human Insulin Market: Humalog, 2019-2026, USD mn 46

Figure 24. North America Modern Human Insulin Market: Other Brands, 2019-2026, USD mn 47

Figure 25. North America Human Insulin Market: Traditional Human Insulin, 2019-2026, USD mn 48

Figure 26. North America Traditional Human Insulin Market: Short-acting, 2019-2026, USD mn 50

Figure 27. North America Traditional Human Insulin Market: Intermediate & Rapid-acting, 2019-2026, USD mn 51

Figure 28. North America Traditional Human Insulin Market: Premixed, 2019-2026, USD mn 52

Figure 29. North America Traditional Human Insulin Market: Humulin, 2019-2026, USD mn 53

Figure 30. North America Traditional Human Insulin Market: Insuman, 2019-2026, USD mn 54

Figure 31. North America Traditional Human Insulin Market: Novolin/Actrapid/Insulatard, 2019-2026, USD mn 55

Figure 32. Breakdown of North America Human Insulin Delivery Devices Market by Product, 2019-2026, % of Revenue 56

Figure 33. Contribution to North America Human Insulin Delivery Devices Cumulative Revenue by Product, 2020-2026, Value (USD mn) and Share (%) 57

Figure 34. North America Human Insulin Delivery Devices Market: Syringes, 2019-2026, USD mn 58

Figure 35. North America Human Insulin Delivery Devices Market: Pens, 2019-2026, USD mn 59

Figure 36. North America Human Insulin Delivery Devices Market: Pumps, 2019-2026, USD mn 60

Figure 37. North America Human Insulin Delivery Devices Market: Other Devices, 2019-2026, USD mn 62

Figure 38. Breakdown of North America Human Insulin Market by Application, 2019-2026, % of Revenue 63

Figure 39. Contribution to North America 2020-2026 Cumulative Revenue by Application, Value (USD mn) and Share (%) 64

Figure 40. North America Human Insulin Market: Type 1 Diabetes, 2019-2026, USD mn 65

Figure 41. North America Human Insulin Market: Type 2 Diabetes, 2019-2026, USD mn 66

Figure 42. North America Human Insulin Market: Gestational Diabetes and Prediabetes, 2019-2026, USD mn 67

Figure 43. Breakdown of North America Human Insulin Market by Distribution Channel, 2019-2026, % of Revenue 68

Figure 44. Contribution to North America 2020-2026 Cumulative Revenue by Distribution Channel, Value (USD mn) and Share (%) 69

Figure 45. North America Human Insulin Market: Hospital Pharmacies, 2019-2026, USD mn 70

Figure 46. North America Human Insulin Market: Retail Pharmacies, 2019-2026, USD mn 71

Figure 47. North America Human Insulin Market: Online Pharmacies, 2019-2026, USD mn 72

Figure 48. Breakdown of North America Human Insulin Market by Country, 2019 and 2026, % of Revenue 74

Figure 49. Contribution to North America 2020-2026 Cumulative Revenue by Country, Value (USD mn) and Share (%) 75

Figure 50. U.S. Human Insulin Market, 2019-2026, USD mn 77

Figure 51. Canada Human Insulin Market, 2019-2026, USD mn 80

Figure 52. Growth Stage of North America Human Insulin Industry over the Forecast Period 82


List Of Table

Table 1. Snapshot of North America Human Insulin Market, 2019-2026 14

Table 2. Main Product Trends and Market Opportunities in North America Human Insulin Market 22

Table 3. North America Human Insulin Market by Product Type, 2019-2026, USD mn 29

Table 4. North America Human Insulin Drugs Market by Product, 2019-2026, USD mn 33

Table 5. North America Human Insulin Drugs Market: Modern Human Insulin by Type, 2019-2026, USD mn 36

Table 6. North America Human Insulin Drugs Market: Modern Human Insulin by Brand, 2019-2026, USD mn 36

Table 7. North America Human Insulin Drugs Market: Traditional Human Insulin by Type, 2019-2026, USD mn 49

Table 8. North America Human Insulin Drugs Market: Traditional Human Insulin by Brand, 2019-2026, USD mn 49

Table 9. North America Human Insulin Delivery Devices Market by Product, 2019-2026, USD mn 56

Table 10. North America Human Insulin Delivery Devices Market: Pens by Product, 2019-2026, USD mn 59

Table 11. North America Human Insulin Market by Application, 2019-2026, USD mn 63

Table 12. North America Human Insulin Market by Distribution Channel, 2019-2026, USD mn 68

Table 13. North America Human Insulin Market by Country, 2019-2026, USD mn 74

Table 14. U.S. Human Insulin Market by Product Type, 2019-2026, USD mn 78

Table 15. U.S. Human Insulin Market by Application, 2019-2026, USD mn 78

Table 16. U.S. Human Insulin Market by Distribution Channel, 2019-2026, USD mn 78

Table 17. Canada Human Insulin Market by Product Type, 2019-2026, USD mn 81

Table 18. Canada Human Insulin Market by Application, 2019-2026, USD mn 81

Table 19. Canada Human Insulin Market by Distribution Channel, 2019-2026, USD mn 81

Table 20. North America Human Insulin Market by Key Vendor, 2019, USD mn 84

Table 21. Astra Zeneca PLC: Company Snapshot 88

Table 22. Astra Zeneca PLC: Business Segmentation 88

Table 23. Astra Zeneca PLC: Product Portfolio 89

Table 24. Astra Zeneca PLC: Revenue, 2016-2018, USD mn 89

Table 25. Astra Zeneca PLC: Recent Developments 89

Table 26. Risk Evaluation for Investing in North America Market, 2019-2026 100

Table 27. Critical Success Factors and Key Takeaways 103

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS


Companies

Astra Zeneca PLC

Biocon

Eli Lilly

Exir

Julphar

Novo Nordisk AS

Pfizer

Sanofi Aventis

Sedico

Wockhardt